Market News AIOpen the app

IAM stock news · Iambic Therapeutics

Stories about Iambic Therapeutics (IAM) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for IAM

Follow Iambic Therapeutics (IAM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IAM
Free on the App Store and Google Play, or on the web.
  1. Nov 18, 2026, 9:11 AM ET · Market

    Iambic Therapeutics shared early research on its drugs IAM-C1 and IAM217 at the ENA 2026 event.

    Good for IAM

    Iambic reported tumor activity for IAM-C1 and tumor shrinkage for IAM217 in preclinical models. This is encouraging progress, but neither has shown benefits in patients.

  2. Oct 16, 2026, 5:06 PM ET · Market

    Iambic Therapeutics, Inc. says it finished its first public stock sale and updated its company rules.

    Neutral

    Iambic updated its charter and bylaws as its IPO closed and listed ways it may share public information. The filing gives no new business or medicine news, so it does not change the outlook.